STOCKS TELEGRAPH

Tag: NeuBase stock

  • What Happened To Make NeuBase (NBSE) Stock Surge 10% After Hours?

    What Happened To Make NeuBase (NBSE) Stock Surge 10% After Hours?

    NeuBase Therapeutics Inc. (NBSE) closed Friday’s after-hours trading at $5.87, up 9.72%. NeuBase’s stock price finished last trading session up 5.31% at $5.35. A range of $4.96-$5.39 was observed for NBSE stock.

    NBSE stock traded 2.29 million shares, which was above its daily average of 0.34 million shares over 100 days. The NBSE’s shares have advanced by 15.55 percent in the last five days, while they have gained 2.6 percent in the last month. NBSE’s stock gained after the company offered an oncology program that demonstrated functional rescue.

    What was the NBSE program?

    In its mission to accelerate the genetic revolution, NeuBase is developing a new class of precision genetic medicines. These medicines will be able to change or increase gene function depending on the genetic defect. Targeted PATrOL therapies develop by NBSE combine genetic therapies with small molecules to effectively treat disorders at the DNA/RNA level and are highly targeted, therefore combining the advantages of small molecules with the broad organ distribution capabilities of genetic therapies. NBSE first focused on redefining medicine for patients suffering from debilitating neurological, neuromuscular, or oncologic conditions with what it calls specific genes that silence disease-causing mutations.

    Earlier this month, NeuBase announced new data and program updates regarding its genetic medicine development pipeline based on PATrOL technology.

    • NBSE was able to find ways to utilize the PATrOL platform to identify drug candidates that could interfere with DNA transcription, RNA translation, and mutant protein production, including dislodging bound proteins to aid mis-splicing.
    • In addition, NBSE has made significant progress since its last report, showing functional recovery after subcutaneous dosing in patients suffering from myotonic dystrophy type 1.
    • The NBSE data demonstrated that compounds could cross the blood-brain barrier in vivo by allele-selective mutant protein knock-down in Huntington’s disease.
    • In 2022, NBSE will have its DM1 program in the clinic as a result of the tremendous momentum it is building across its expanding development pipeline.
    • Also, the NBSE will continue to explore diseases where the PATrOL platform can provide significant therapeutic benefits.

    How NBSE will excel through its platform?

    PATrOL, NeuBase (NBSE)’s platform technology, enables it to generate precision genetic medicines with unrivaled flexibility aimed at distinct genetic disorders based on data from several programs in its pipeline. As demonstrated by the successful application of NBSE’s platform to three disease indications with different mechanisms of disease, its platform can regulate gene function in vivo at the RNA and DNA levels with high precision.

  • Why NeuBase Therapeutics, Inc. (NBSE) stock declined in Wednesday’s aftermarket?

    Why NeuBase Therapeutics, Inc. (NBSE) stock declined in Wednesday’s aftermarket?

    Shares of the NeuBase Therapeutics, Inc. (NBSE) stock were declining in yesterday’s aftermarket trading session after the spread of the news that Neubase stock announced the proposed public offering of its common stock. NBSE stock price saw a downtrend of 9.17% to drop at $5.45 a share in the late hours of Wednesday on April 21, 2021. NBSE was green in the previous trading session and recorded a gain of 3.09% at closing. Let’s discuss the current events in detail.

    What’s happening?

    NeuBase Therapeutics, Inc is a pre-clinical stage pharmaceutical company mainly focused on the treatment of rare genetic diseases as well as cancers resulting from mutant genes through the development of various therapies.NBSE stock recently started the underwritten public offering of shares of its common stock. The proposed public offering is subjected to the market along with various other conditions and the actual size of the offering, and the completion date of it has not been disclosed by the NBSE stock. The underwriters will be granted the 30-day option for the purchasing of additional 15% shares of the common stock of NeuBase and the terms and conditions for this option would be similar to the terms and conditions of the public offering.

    NeuBase stock intends to use the net proceeds from the proposed public offering in its general corporate purposes as well as working capital. Part of the proceeds will be used in the product candidates and pipeline expansion of NBSE stock.

    Previous News of NBSE stock:

    On April 08, 2021, NeuBase stock did the announcement that it will host the virtual R&DDay for investors and analysts on June 8, 2021, from 12:30 p.m. to 2:30 p.m. EDT.NBSE stock will present its new data and in-depth review of the development of pipeline candidate products of Huntington’s disease, myotonic dystrophy type 1, and the previously undruggable target in a new oncology program. The expansion of the management team will also be discussed in the event.

    Conclusion:

    Individuals are responding to the public offering announced by the NBSE stock. The completion date and the specific per-share price have not been assured in the offering. The upcoming event on June 8 will further clarify the position of NBSE stock.